Literature DB >> 31538207

[Rheumathism and pneumology].

A Jakubczyc1, C Neurohr2.   

Abstract

BACKGROUND: Due to the broad range of diagnostic and therapeutic aspects with an increased risk of mortality, lung manifestations of rheumatic diseases are an exciting and important field in the clinical routine of pulmonologists and rheumatologists.
OBJECTIVE: Discussion of different presentations in the lung, diagnostics and management of lung manifestation associated with rheumatic diseases.
MATERIAL AND METHODS: Analysis and presentation of current literature on the subject.
RESULTS: The manuscript presents forms of lung involvement associated with rheumatic diseases, in particular the connective tissue disease-associated interstitial lung disease. Considering the negative impact on survival, rapid and adequate diagnosis is of great importance. In the case of a known underlying rheumatic disease, histological confirmation of interstitial changes is not always necessary. In addition to the patient's history, pulmonary function testing and diagnostic imaging with high-resolution CT-scan (HR-CT) are cornerstones of the diagnostic process. The final diagnosis and therapeutic approach should be determined by a multidisciplinary discussion process. The basis of the treatment is immunosuppressants, however the use antifibrotic drugs is currently under investigation in clinical trials. In the case of advanced lung disease, lung transplantation should be evaluated promptly.
CONCLUSION: In the case of pulmonary involvement with rheumatic disease, the teamwork of pulmonologists, rheumatologists and radiologists is of particular importance.

Entities:  

Keywords:  Antirheumatic drugs; Connective tissue diseases; Immunosuppressants; Interstitial lung diseases; Pulmonary function tests

Mesh:

Substances:

Year:  2019        PMID: 31538207     DOI: 10.1007/s00132-019-03806-6

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  15 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

2.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Oliver Distler; Kristin B Highland; Martina Gahlemann; Arata Azuma; Aryeh Fischer; Maureen D Mayes; Ganesh Raghu; Wiebke Sauter; Mannaig Girard; Margarida Alves; Emmanuelle Clerisme-Beaty; Susanne Stowasser; Kay Tetzlaff; Masataka Kuwana; Toby M Maher
Journal:  N Engl J Med       Date:  2019-05-20       Impact factor: 91.245

Review 3.  Lung Manifestations in the Rheumatic Diseases.

Authors:  Tracy J Doyle; Paul F Dellaripa
Journal:  Chest       Date:  2017-05-25       Impact factor: 9.410

Review 4.  [Pulmonary fibrosis in rheumatic diseases].

Authors:  D Grund; E Siegert
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

Review 5.  [What rheumatologists can learn from pneumologists].

Authors:  G Leuschner; C Neurohr
Journal:  Z Rheumatol       Date:  2018-08       Impact factor: 1.372

6.  [DGP Interstitial Lung Disease Patient Questionnaire].

Authors:  M Kreuter; U Ochmann; D Koschel; J Behr; F Bonella; M Claussen; U Costabel; S Jungmann; M Kolb; D Nowak; F Petermann; M Pfeiffer; M Polke; A Prasse; J Schreiber; J Wälscher; H Wirtz; D Kirsten
Journal:  Pneumologie       Date:  2018-02-21

Review 7.  Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment.

Authors:  You-Jung Ha; Yun Jong Lee; Eun Ha Kang
Journal:  Biomed Res Int       Date:  2018-05-08       Impact factor: 3.411

Review 8.  Acute Exacerbation in Interstitial Lung Disease.

Authors:  Gabriela Leuschner; Jürgen Behr
Journal:  Front Med (Lausanne)       Date:  2017-10-23

9.  Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Authors:  Kevin R Flaherty; Kevin K Brown; Athol U Wells; Emmanuelle Clerisme-Beaty; Harold R Collard; Vincent Cottin; Anand Devaraj; Yoshikazu Inoue; Florence Le Maulf; Luca Richeldi; Hendrik Schmidt; Simon Walsh; William Mezzanotte; Rozsa Schlenker-Herceg
Journal:  BMJ Open Respir Res       Date:  2017-09-17

10.  Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis.

Authors:  Noriyuki Enomoto; Yoshiyuki Oyama; Yasunori Enomoto; Hideki Yasui; Masato Karayama; Masato Kono; Hironao Hozumi; Yuzo Suzuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Takafumi Suda
Journal:  Chron Respir Dis       Date:  2018-10-31       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.